AVIEW LCS vs DeepRhythmAI
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your practice requires a comprehensive AI-powered solution for multi-faceted cardiopulmonary assessment from low-dose CT scans. This tool is ideal for radiologists and pulmonologists seeking automated detection and analysis of lung nodules, emphysema quantification, and coronary artery calcification scoring within a single platform, streamlining lung cancer screening and follow-up workflows.
View AVIEW LCS →Choose DeepRhythmAI if…
Choose DeepRhythmAI if your cardiology practice prioritizes highly accurate and efficient AI-powered analysis of ECG data for cardiac arrhythmia detection and classification. This cloud-based solution is best suited for clinicians aiming to significantly reduce missed diagnoses and accelerate reporting times across various ECG devices, enhancing overall workflow efficiency in arrhythmia diagnostics.
View DeepRhythmAI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | DeepRhythmAI |
|---|---|---|
| Pricing | Subscription or one-off payment | Contact vendor for pricing information |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Cloud-based, hardware-agnostic, SaaS, on-prem, hybrid |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS offers more flexible deployment options, including cloud, hybrid, local dedicated hardware, and virtualized environments, which caters to a wider range of IT infrastructures and user preferences. Its comprehensive, automated report generation and integration with PACS/RIS also contribute to streamlined workflows and ease of use within existing radiology systems. DeepRhythmAI, while emphasizing workflow efficiency, is strictly cloud-based, which might limit its appeal for some organizations.
Clinical Value
DeepRhythmAIDeepRhythmAI demonstrates a highly impactful clinical value by significantly reducing missed diagnoses of cardiac arrhythmias, with reported reductions ranging from 14x to 114x fewer missed events. This direct, quantified improvement in diagnostic accuracy, coupled with its training on over 250 billion annotated heartbeats, highlights its strong clinical efficacy. While AVIEW LCS offers multi-disease assessment from a single CT scan, DeepRhythmAI's specific and substantial impact on reducing diagnostic errors in a critical area gives it an edge.
Pricing & Value
TieBoth AVIEW LCS and DeepRhythmAI lack transparent public pricing, requiring direct contact for quotes or specifying 'enterprise' pricing without details. Without specific cost information or detailed return-on-investment studies for either tool, it is impossible to definitively determine which offers superior value. Therefore, a tie is appropriate for this dimension.
Enterprise Readiness
AVIEW LCSAVIEW LCS explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical for enterprise adoption, particularly in the US healthcare market. Furthermore, its diverse deployment options (cloud, hybrid, local, virtualized) offer greater flexibility for integration into various enterprise IT environments. While DeepRhythmAI has an API and a global customer base, AVIEW LCS's explicit compliance and deployment versatility provide a stronger foundation for enterprise readiness.
Innovation
DeepRhythmAIDeepRhythmAI showcases significant innovation through its use of advanced AI models, specifically CNN and Transformer models, and its training on an exceptionally large dataset of over 250 billion annotated heartbeats. This extensive training and sophisticated algorithmic approach contribute to its superior accuracy in arrhythmia detection. AVIEW LCS's multi-disease assessment from a single CT scan is innovative, but DeepRhythmAI's technical depth in AI methodology and data scale for a specific, complex diagnostic challenge stands out.
Support & Docs
TieNeither the provided structured facts nor web searches offered sufficient specific details regarding the depth, availability, or quality of support and documentation for either AVIEW LCS or DeepRhythmAI. Both companies indicate offering technical support and resources, but without comparative information on SLAs, support tiers, or comprehensive documentation, a clear winner cannot be determined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | DeepRhythmAI |
|---|---|---|
| Name | AVIEW LCS | DeepRhythmAI |
| Company | Coreline Soft Co. | Medicalgorithmics S.A. |
| Tagline | AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment | Revolutionizing cardiac arrhythmia diagnostics with AI-powered ECG analysis. |
| Description | Coreline Soft's AVIEW LCS is an AI-powered solution for the detection and analysis of lung nodules. The AVIEW LCS Plus platform provides integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, enhancing diagnostic accuracy and streamlining radiology workflows. | DeepRhythmAI is an FDA-cleared, cloud-based AI algorithm by Medicalgorithmics S.A. that revolutionizes cardiac arrhythmia detection and classification from ECG data, offering superior accuracy and efficiency for physicians. |
| Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI | Cardiology AI, Clinical Decision Support & Reference |
| Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology |
| Key Features | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass), Automated comparison of nodules in follow-up CT scans, Comprehensive, automated report generation, Integration with PACS/RIS and third-party platforms | AI-powered arrhythmia detection and classification, Utilizes CNN and Transformer models, Trained on 250 billion+ annotated heartbeats, Device-agnostic and integrates with various ECG devices, Cloud-based software, Faster ECG reporting and analysis, Reduces missed diagnoses (14x to 114x fewer), Streamlines clinical workflows (up to 65% efficiency increase) |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and DeepRhythmAI.